MRZ-9547

MRZ-9547, also known as -phenylpiracetam, -phenotropil, or -fonturacetam, is a selective dopamine reuptake inhibitor that was developed by Merz Pharma. It is the -enantiomer of the racetam and nootropic phenylpiracetam.
The drug was under development for the treatment of fatigue associated with Parkinson's disease and was in phase 1 clinical trials for this indication in June 2014. However, no recent development has been reported as of November 2017. There was also interest in MRZ-9547 for treatment of fatigue in people with depression and other conditions, but this was not pursued.
Similarly to other dopamine reuptake inhibitors and related agents, MRZ-9547 has been found to have pro-motivational effects in animals and to reverse motivational deficits induced by the dopamine depleting agent tetrabenazine.
The drug, as the enantiopure -enantiomer of phenylpiracetam, was first described in the scientific literature by 2014.